港股異動丨四環醫藥創逾4個月新高,樂提葆獨家銷售協議續約至2030年年底
四環醫藥(0460.HK)升7.47%報0.59港元,股價創逾4個月新高,總市值逼近55億港元。消息上,四環醫藥宣佈與韓國生物製藥公司Hugel簽署的關於注射用A型肉毒毒素樂提葆®的獨家銷售協議,經協議雙方一致確認,已續約至2030年年底。樂提葆®是中國市場中第四個獲批上市的肉毒毒素產品,也是目前中國市場上唯一一個獲批的韓國肉毒毒素產品。該產品由Hugel研發生產,是韓國當地連續八年市佔率第一的肉毒毒素產品。2024年上半年,樂提葆®在中國的銷售收入持續維持高增長,同比增長超過50%。根據市場信息顯示,樂提葆®在中國的市場佔有率已超過10%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.